An evidence-based medicine approach to beta-blocker therapy in patients with cirrhosis

Jayant A. Talwalkar, Patrick Sequeira Kamath

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Disease management strategies have gained attention in recent years because of their potential to improve health-related quality of life and prevent excessive resource use. Despite recognition as an important cause of mortality, cirrhosis with portal hypertension has not been widely discussed as a condition amenable to planned care management. Given the effect of variceal hemorrhage as the most immediate life-threatening complication of portal hypertension, a number of high-quality controlled clinical trials have confirmed the efficacy of beta-blocker therapy for primary and secondary prophylaxis. Despite the existence of practice guidelines that incorporate this information, specific clinical scenarios that demand consideration for beta-blocker therapy have not been well described. In this article, a number of hypothetical patient-based cases drawn from the authors' experiences are utilized to illustrate these issues.

Original languageEnglish (US)
Pages (from-to)759-766
Number of pages8
JournalAmerican Journal of Medicine
Volume116
Issue number11
DOIs
StatePublished - Jun 1 2004

Fingerprint

Evidence-Based Medicine
Portal Hypertension
Fibrosis
Controlled Clinical Trials
Disease Management
Practice Guidelines
Quality of Life
Hemorrhage
Mortality
Therapeutics

ASJC Scopus subject areas

  • Nursing(all)

Cite this

An evidence-based medicine approach to beta-blocker therapy in patients with cirrhosis. / Talwalkar, Jayant A.; Kamath, Patrick Sequeira.

In: American Journal of Medicine, Vol. 116, No. 11, 01.06.2004, p. 759-766.

Research output: Contribution to journalArticle

@article{4d027cedd1ad4086b762db719e987903,
title = "An evidence-based medicine approach to beta-blocker therapy in patients with cirrhosis",
abstract = "Disease management strategies have gained attention in recent years because of their potential to improve health-related quality of life and prevent excessive resource use. Despite recognition as an important cause of mortality, cirrhosis with portal hypertension has not been widely discussed as a condition amenable to planned care management. Given the effect of variceal hemorrhage as the most immediate life-threatening complication of portal hypertension, a number of high-quality controlled clinical trials have confirmed the efficacy of beta-blocker therapy for primary and secondary prophylaxis. Despite the existence of practice guidelines that incorporate this information, specific clinical scenarios that demand consideration for beta-blocker therapy have not been well described. In this article, a number of hypothetical patient-based cases drawn from the authors' experiences are utilized to illustrate these issues.",
author = "Talwalkar, {Jayant A.} and Kamath, {Patrick Sequeira}",
year = "2004",
month = "6",
day = "1",
doi = "10.1016/j.amjmed.2004.03.006",
language = "English (US)",
volume = "116",
pages = "759--766",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - An evidence-based medicine approach to beta-blocker therapy in patients with cirrhosis

AU - Talwalkar, Jayant A.

AU - Kamath, Patrick Sequeira

PY - 2004/6/1

Y1 - 2004/6/1

N2 - Disease management strategies have gained attention in recent years because of their potential to improve health-related quality of life and prevent excessive resource use. Despite recognition as an important cause of mortality, cirrhosis with portal hypertension has not been widely discussed as a condition amenable to planned care management. Given the effect of variceal hemorrhage as the most immediate life-threatening complication of portal hypertension, a number of high-quality controlled clinical trials have confirmed the efficacy of beta-blocker therapy for primary and secondary prophylaxis. Despite the existence of practice guidelines that incorporate this information, specific clinical scenarios that demand consideration for beta-blocker therapy have not been well described. In this article, a number of hypothetical patient-based cases drawn from the authors' experiences are utilized to illustrate these issues.

AB - Disease management strategies have gained attention in recent years because of their potential to improve health-related quality of life and prevent excessive resource use. Despite recognition as an important cause of mortality, cirrhosis with portal hypertension has not been widely discussed as a condition amenable to planned care management. Given the effect of variceal hemorrhage as the most immediate life-threatening complication of portal hypertension, a number of high-quality controlled clinical trials have confirmed the efficacy of beta-blocker therapy for primary and secondary prophylaxis. Despite the existence of practice guidelines that incorporate this information, specific clinical scenarios that demand consideration for beta-blocker therapy have not been well described. In this article, a number of hypothetical patient-based cases drawn from the authors' experiences are utilized to illustrate these issues.

UR - http://www.scopus.com/inward/record.url?scp=2442608935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442608935&partnerID=8YFLogxK

U2 - 10.1016/j.amjmed.2004.03.006

DO - 10.1016/j.amjmed.2004.03.006

M3 - Article

VL - 116

SP - 759

EP - 766

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 11

ER -